You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CATAFLAM Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Cataflam, and what generic alternatives are available?

Cataflam is a drug marketed by Amici and Novartis and is included in two NDAs.

The generic ingredient in CATAFLAM is diclofenac potassium. There are forty-seven drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the diclofenac potassium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Cataflam

A generic version of CATAFLAM was approved as diclofenac potassium by TEVA on August 6th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CATAFLAM?
  • What are the global sales for CATAFLAM?
  • What is Average Wholesale Price for CATAFLAM?
Drug patent expirations by year for CATAFLAM
Recent Clinical Trials for CATAFLAM

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Cairo UniversityPhase 4
Pharmactive Ilac Sanayi ve Tic A.S.Phase 1/Phase 2
Merck Healthcare KGaA, Darmstadt Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1

See all CATAFLAM clinical trials

Pharmacology for CATAFLAM

US Patents and Regulatory Information for CATAFLAM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amici CATAFLAM diclofenac potassium TABLET;ORAL 076561-002 Jul 21, 2021 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis CATAFLAM diclofenac potassium TABLET;ORAL 020142-002 Nov 24, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Amici CATAFLAM diclofenac potassium TABLET;ORAL 076561-001 Mar 18, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Novartis CATAFLAM diclofenac potassium TABLET;ORAL 020142-001 Nov 24, 1993 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.